Decibel Therapeutics, Inc.
https://www.decibeltx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Decibel Therapeutics, Inc.
Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’
Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline.
Regeneron Gene Therapy Reaches New Heights In Restoring Hearing
The US biotech’s DB-OTO has made headlines worldwide after a baby with profound genetic deafness experienced improved hearing to normal levels within 24 weeks after a single intracochlear injection.
Dupixent COPD Approval Could Be Delayed, Regeneron Cautions
The US Food and Drug Administration has requested additional efficacy information on the supplemental filing in the potentially large new indication.
Regeneron Strikes A CHORD With Deafness Gene Therapy
A very early success with a gene therapy for a rare form of deafness puts Regeneron ahead of Lilly and Sensorion.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice